Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Outcomes for patients with acute myeloid leukemia (AML) have improved due to advances in therapeutic approaches in combination with improvements in supportive care. However, relapse remains a significant clinical challenge and research has focused on maintenance strategies to extend remission and overall survival in patients with AML.1
Nicholas Short, MD
MD Anderson Cancer Center, Houston, TX
Charles Craddock, CBE, FRCP(UK), FRCPath, DPhil
Queen Elizabeth Hospital, Birmingham, UK
Thomas Cluzeau, MD, PhD
University Hospital of Nice, Nice, France
Thomas Cluzeau, MD, PhD
University Hospital of Nice, Nice, France
Mark Levis, MD, PhD
Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
Alessandro Isidori, MD, PhD
Marche Nord Hospital, Pesaro, Italy
Pramila Krishnamurthy, MA, FRCPath, MRCP, PhD
King’s College Hospital NHS Foundation Trust, London, UK
Reference:
1. Reville, P.K. and Kadia, T.M. Maintenance therapy in AML. Frontiers in Oncology 2021;10:619085. doi:10.3389/fonc.2020.619085.
5:18
Glossary
AML, acute myeloid leukemia
This educational activity has received independent medical education support from Bristol Myers Squibb. This supporter has no influence over the production of the content.